B08 IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: KARMMA-3 A PHASE 3 RANDOMIZED CONTROLLED TRIAL
B08 IDECABTAGENE VICLEUCEL 与标准方案治疗三类药物暴露后复发难治性多发性骨髓瘤患者:KARMMA-3 3期随机对照试验
期刊:Polymers
影响因子:4.9
doi:10.3390/polym15163416
Kang, Hyo-Kyung; Byeon, Jun-Ho; Hwang, Hyun-Jun; Jang, Yoon Hee; Kim, Jin-Yeol; Rodríguez-Otero, P; Ailawadhi, S; Arnulf, B; Patel, K; Cavo, M; Nooka, AK; Manier, S; Callander, N; Costa, LJ; Vij, R; Bahlis, NJ; Moreau, P; Solomon, SR; Delforge, M; Berdeja, J; Truppel-Hartmann, A; Yang, Z; Favre-Kontula, L; Wu, F; Piasecki, J; Cook, M; Giralt, S